Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark M Pomerantz

Showing results (31-40 of 63) with videos related to

Pageof 7
Sort By:
Cell|June 19, 2018
A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate CancerDavid Y Takeda, Sándor Spisák, Ji-Heui Seo, et al.
Cancer|January 1, 2024
Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized phase 2 trialRana R McKay, Wanling Xie, Xiaoyu Yang, et al.
Cancer Discovery|August 31, 2019
CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 InactivationReyaz Ur Rasool, Ramakrishnan Natesan, Qu Deng, et al.
Plos Genetics|November 19, 2010
Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesisMark M Pomerantz, Yashaswi Shrestha, Richard J Flavin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2019
A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2)Ying Z Mazzu, Joshua Armenia, Goutam Chakraborty, et al.
Nature Genetics|September 7, 2022
Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulationSylvan C Baca, Cassandra Singler, Soumya Zacharia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2021
Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation AnalysisJacob E Berchuck, Sylvan C Baca, Heather M McClure, et al.
The Journal of Urology|March 8, 2021
Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate CancerRana R McKay, Wanling Xie, Huihui Ye, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 26, 2012
Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesisChiara Grisanzio, Lillian Werner, David Takeda, et al.
Cancer Research|June 25, 2009
Evaluation of the 8q24 prostate cancer risk locus and MYC expressionMark M Pomerantz, Christine A Beckwith, Meredith M Regan, et al.
Pageof 7

Showing results (31-40 of 63) with videos related to

Sort By:
Pageof 7
Cell|June 19, 2018
A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate CancerDavid Y Takeda, Sándor Spisák, Ji-Heui Seo, et al.
Cancer|January 1, 2024
Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized phase 2 trialRana R McKay, Wanling Xie, Xiaoyu Yang, et al.
Cancer Discovery|August 31, 2019
CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 InactivationReyaz Ur Rasool, Ramakrishnan Natesan, Qu Deng, et al.
Plos Genetics|November 19, 2010
Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesisMark M Pomerantz, Yashaswi Shrestha, Richard J Flavin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2019
A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2)Ying Z Mazzu, Joshua Armenia, Goutam Chakraborty, et al.
Nature Genetics|September 7, 2022
Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulationSylvan C Baca, Cassandra Singler, Soumya Zacharia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2021
Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation AnalysisJacob E Berchuck, Sylvan C Baca, Heather M McClure, et al.
The Journal of Urology|March 8, 2021
Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate CancerRana R McKay, Wanling Xie, Huihui Ye, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 26, 2012
Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesisChiara Grisanzio, Lillian Werner, David Takeda, et al.
Cancer Research|June 25, 2009
Evaluation of the 8q24 prostate cancer risk locus and MYC expressionMark M Pomerantz, Christine A Beckwith, Meredith M Regan, et al.
Pageof 7